StreetInsider.com News Articles

Creative Medical reports Ultrasome knee study results in 30 patients

Tue, 20 Oct 2026 09:15:58 -0400

Creative Medical Technology Holdings (NASDAQ: CELZ) released additional findings from a pilot study of its investigational Ultrasome™ platform in patients with knee osteoarthritis, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy on Oct. 10, 2026, in Lima, Peru.

The open-label, single-arm study enrolled 30 patients with bilateral knee osteoarthritis over six months. Twenty-eight of 30 participants, or 93%, met study-defined response criteria. The group's average pain score declined by approximately 65% from baseline to six months. The study did not include a randomized or sham-controlled comparator group.

Additional reported outcomes included a 52% reduction in average

Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

Tue, 20 Oct 2026 09:15:00 -0400

PHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted additional clinical and laboratory findings for Ultrasome™, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy held October 10, 2026, in Lima, Peru.

The study evaluated 30 patients with bilateral knee osteoarthritis over six months and found that 28 of 30 participants (93%) met study-defined response criteria. Importantly, the group’s average reported pain score declined

Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

Tue, 20 Oct 2026 09:15:00 -0400

Form SCHEDULE 13D CREATIVE MEDICAL TECHNOL Filed by: Warbington Timothy

Thu, 01 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27136986.html

Form 4 CREATIVE MEDICAL TECHNOL For: Sep 24 Filed by: Warbington Timothy

Fri, 25 Sep 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260925/27108344.html

Form 8-K CREATIVE MEDICAL TECHNOL For: Sep 24

Fri, 25 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260925/27108104.html

Creative Medical files provisional patent for Ultrasome platform

Thu, 17 Sep 2026 09:02:21 -0400

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) filed a new U.S. provisional patent application covering its Ultrasome cell-free regenerative medicine platform, according to a company statement.

The application seeks protection across several aspects of the Ultrasome platform, including product composition, biological potency, manufacturing and quality-control methodologies, stability characteristics, delivery approaches, and therapeutic applications.

As a provisional application, the filing establishes an initial U.S. priority date and gives the company the opportunity to pursue U.S. and international patent protection through subsequent filings. The application has not been examined by the U.S. Patent and Trademark Office, and no assurance exists regarding the scope or

Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

Thu, 17 Sep 2026 09:00:00 -0400

PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome™, the Company’s proprietary cell-free regenerative medicine platform.

The newly filed application builds upon Creative Medical’s existing regenerative medicine intellectual property and seeks protection across multiple aspects of the Ultrasome platform, including proprietary product composition, biological potency, manufacturing and quality-control methodologies, stability characteristics, delivery approaches and therapeutic applications.

Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

Thu, 17 Sep 2026 09:00:00 -0400

Creative Medical completes enrollment in ADAPT back pain trial

Thu, 20 Aug 2026 09:15:20 -0400

Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.

Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.